Zai Lab to present zocilurtatug pelitecan clinical data at AACR meeting

Zai Lab (ZLAB) announced clinical data indicating zocilurtatug pelitecan, a DLL3-targeting antibody-drug conjugate, provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases criteria, as well as promising data in patients with other neuroendocrine carcinomas. These findings, as well as preclinical data evaluating ZL-6201 and ZL-1222, will be presented at the American Association for Cancer Research Annual Meeting 2026 in San Diego. “The zoci data that we will present at AACR, alongside our ZL-6201 and ZL-1222 preclinical data, highlight the breadth, diversity and potential of our global oncology pipeline,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “The rapid progression of zoci into pivotal development, with three registration-enabling studies planned by the end of this year, is a prime example of our strategy to deliver our first global oncology launch. This accelerated progress is made possible by our unique integrated U.S.-China infrastructure, which allows us to evolve drug discovery into life-changing medicines with a focus on speed and quality.”